Full-Time

Executive Director

Quality Assurance

Confirmed live in the last 24 hours

Verve Therapeutics

Verve Therapeutics

201-500 employees

Develops gene editing therapies for cardiovascular disease

Biotechnology
Healthcare

Expert

Boston, MA, USA

Hybrid role requiring three days in the Boston office.

Category
QA & Testing
Quality Assurance
Requirements
  • BA/BS in scientific discipline with an advanced degree preferred.
  • 15+ years demonstrated GMP quality experience in the pharmaceutical/biopharmaceutical industry.
  • Experienced with drug development for complex biologics.
  • Experience interacting with CDMOs, QPs, and relevant regulatory authorities.
  • Experience with review of regulatory requirements and filings.
  • Strong interpersonal and communication skills (written and verbal), team player, with good decision-making ability that is results oriented without compromising quality.
  • Demonstrated project management and organizational skills.
  • Strong aptitude with Microsoft Office applications (Word, Excel, etc.).
  • Ability to travel, as needed.
Responsibilities
  • Provide leadership and oversight for GxP QA including: Development and implementation of a phase-appropriate Quality Management System, including SOPs, change control, investigations, CAPA, compliance, document management, training management and validation.
  • Quality Operations function responsible for disposition of GMP materials and products based on review of batch records, test records, regulatory filings, GMP requirements and other Verve requirements.
  • Vendor qualifications and external/internal audits and regulatory inspections.
  • QA support for Verve GxP QC laboratory operations.
  • Manage budget and resources to address strategic needs of QA, including hiring decisions, talent management, and mentoring/development of QA team members.
  • Establish and implement SOPs and phase-appropriate quality-related systems and standards to maintain compliance with FDA, ICH, EU, and other country-specific regulations including GxP practices.
  • Identify and address gaps or areas for improvement in systems, procedures, and quality initiatives.
  • Collaborate with Verve Manufacturing, QC, Process Development and R&D on issues such as review and approval of batch records, certificates of analysis/testing and compliance, in-process and release test methods, specifications, stability protocols/reports, analytical method validations, technical study reports, trending reports, etc.
  • Support review of regulatory filing activities, as needed.
  • Establish and maintain Quality Technical Agreements with CDMOs and CTLs.
  • Represent Quality at internal and external project team meetings and build relationships with Quality counterparts at CDMOs and CTLs.
  • Maintain a Quality Risk Management system to identify and mitigate compliance risks.
  • Other responsibilities as assigned.

Verve Therapeutics focuses on developing gene editing therapies to treat cardiovascular disease. Their approach involves creating single-course treatments that aim to provide lasting solutions, unlike traditional therapies that require ongoing management. The company specifically targets the PCSK9 and ANGPTL3 genes, which are known to help lower blood lipid levels. This focus on gene editing sets Verve apart from competitors who may rely on more conventional treatment methods. The goal of Verve Therapeutics is to offer potentially curative options for patients with cardiovascular conditions, improving their long-term health outcomes.

Company Stage

IPO

Total Funding

$353.6M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

1%

1 year growth

0%

2 year growth

4%
Simplify Jobs

Simplify's Take

What believers are saying

  • Eli Lilly's $60M investment shows confidence in Verve's cardiovascular gene editing approach.
  • CRISPR therapy approvals, like Casgevy, pave the way for Verve's regulatory success.
  • CRISPR's success in genetic blindness supports Verve's potential in cardiovascular treatments.

What critics are saying

  • Rapid CRISPR advancements may increase competition, affecting Verve's market share.
  • Most CRISPR therapies are in early stages, delaying Verve's market entry and revenue.
  • Verve's stock drop post-offering suggests investor concerns about financial stability.

What makes Verve Therapeutics unique

  • Verve focuses on single-course gene editing for cardiovascular diseases, unlike chronic treatments.
  • The company targets PCSK9 and ANGPTL3 genes, crucial for lowering blood lipid levels.
  • Verve's approach offers potentially curative treatments, setting it apart in the biotech sector.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options